#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Spinal muscular atrophy Epilepsy Thrombotic thrombocytopenic purpura Juvenile idiopathic arthritis Prophylaxis against transplant rejection Crigler-Najjar syndrome Acute graft versus host disease in skin B-cell small lymphocytic lymphoma refractory Optic glioma Soft tissue necrosis Chronic inflammatory demyelinating polyradiculoneuropathy Uveitis Kidney transplant rejection Still's disease Bronchiectasis More trials…

    Learn about Rare Diseases

    Antisynthetase syndrome Hypereosinophilic syndrome – Diagnostics Pelizaeus-Merzbacher disease Glycogen storage disease type V – Diagnostics Leiomyosarcoma metastatic – Treatment Myxofibrosarcoma – Diagnostics Chondrosarcoma metastatic – Diagnostics Marginal zone lymphoma refractory – Treatment Cerebral arteriovenous malformation haemorrhagic – Diagnostics Hereditary ataxia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cariprazine Hydrochloride Mk-0616 Siplizumab OLVEREMBATINIB Protrans Eplontersen Rozanolixizumab Exenatide Sunvozertinib Danicopan Cefazolin Sodium Daptomycin Amiloride Hydrochloride Human Vaccinia Immunoglobulin Imgn151 Montelukast Sodium Pariglasgene Brecaparvovec Epoetin Alfa Ergocalciferol Levobupivacaine More therapies…

    Learn about Your Condition

    Plasma cell leukaemia Hepatobiliary disease Vascular calcification Malignant oligodendroglioma Hepatic cirrhosis Type 2 diabetes mellitus Vulvar dysplasia Breast cancer in situ Diabetic retinopathy Colorectal cancer stage II Chondrocalcinosis Lymphoedema Inflammation Systemic scleroderma Langerhans' cell histiocytosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dementia Alzheimer’s type

  • Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer’s disease patients: Long-term safety evaluation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Croatia Czechia France Greece Hungary +5

  • Study of MK-2214 to slow disease progression in people with early Alzheimer’s disease

    Recruiting

    2 1
    Investigated Drugs:
    • Florquinitau (18F)
    Belgium The Netherlands Spain

  • Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer’s Disease

    Recruiting

    4 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • LY3372993
    • N-Methyl-2-(4′-Methylaminophenyl)-6-Hydroxybenzothiazole
    France Germany Italy The Netherlands Spain

  • Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer’s Disease over 72 weeks

    Recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • VHB937
    Czechia France Germany Italy The Netherlands Poland +2

  • Study on Brain Imaging for Alzheimer’s Disease Using Florquinitau (18F) in Patients with Mild Cognitive Impairment and Early Alzheimer’s Symptoms

    Recruiting

    4 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Florquinitau (18F)
    Belgium

  • Study on the Use of 18F-PI-2620 to Detect Alzheimer’s in People with Down Syndrome

    Recruiting

    2 1 1
    Investigated Diseases:
    • Trisomy 21
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Izaflortaucipir (18F)
    Spain
Previous Page
1 2 3 4 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!